Business
Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing
About this update from Bicara Therapeutics Inc.
[{"type":"text","content":"BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that three abstracts relating to the company’s lead product candidate, ficerafusp alfa, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, which will be held from April 25-30, 2025 in Chicago, IL. Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β) and is being evaluated across multiple solid tumor types. Details of the poster presentations are as follows: Title: Dose expansion results of single agent ficerafusp alfa (BCA101), a bifunctional EGFR/TGF-β inhibitor in patients with metastatic or advanced cutaneous squamous cell carcinoma (cSCC) Published Abstract #: CT034Session Category: Clinical TrialsSession Title: Phase 0 and Phase I Clinical TrialsSession Date and Time: 4/28/2025 9:00 a.m. CTLocation: McCormick Place Convention Center, Poster Section 49 This presentation will highlight data from a Phase 1/1b dose expansion cohort of ficerafusp alfa monotherapy in second line or later cSCC patients. Title: Dual blockade of EGFR and TGF-β with ficerafusp alfa has the potential to overcome resistance mechanisms in 1L R/M HNSCC in combination with Pembrolizumab Published Abstract #: 3284Session Category: Clinical ResearchSession Title: Modifiers of the Tumor MicroenvironmentSession Date and Time: 4/28/2025 2:00 p.m. CTLocation: McCormick Place Convention Center, Poster Section 30 This presentation will highlight a translational medicine biomarker dataset that provides insights into the effects of targeted inhibition of TGF-β with ficerafusp alfa. Title: Ficerafusp alfa reverses acquired resistance to the KRAS-G12C inhibitor sotorasib in KRAS-G12C-mutated lung tumors Published Abstract #: 4434Session Category: Experimental and Molecular TherapiesSession Title: Reversal of Drug ResistanceSession Date and Time: 4/29/2025 9:00 a.m. CTLocation: McCormick Place Convention Center, Poster Section 23 This presentation will highlight a preclinical dataset that provides ins...